Related Experiment Video
Updated: Jan 31, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
CRISPR activation screens map the genomic landscape of cancer glycome remodeling
John Daly1, Lidia Piatnitca1, Mohammed Al-Seragi1
1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Abstract:
Many cancers upregulate the expression of sialic acid-containing glycans. These oligosaccharides engage inhibitory sialic acid-binding immunoglobulin-like lectin (Siglec) receptors on immune cells, allowing cancer cells to evade immune surveillance. The genetic mechanisms underlying this process remain poorly defined. In this study, we performed gain-of-function CRISPR activation (CRISPRa) screens to define genetic pathways that regulate expression of Siglec-binding glycans. We show that Siglec ligand expression is controlled through genetic competition between genes that catalyze α2-3 sialylation and GlcNAcylation of galactose residues. Cancer glycome remodeling is also aided by the overexpression of "professional ligands" that facilitate Siglec-glycan binding. Notably, we also find that expression of the CD24 gene is genetically dispensable for cell surface binding of the inhibitory receptor Siglec-10. Finally, we identify the sulfotransferase enzyme GAL3ST4 as a potential driver of immune evasion in glioma cells. Our study provides a unique genomic atlas of cancer-associated glycosylation and identifies immediately actionable targets for cancer immunotherapy.
Insights
Cancer cells evade immune surveillance by altering cell surface sugars to engage inhibitory receptors. This study identifies key genes controlling these "cancer cloaking" glycans, revealing new immunotherapy targets.
Area of Science:
- Immunology
- Cancer Biology
- Genetics
Background:
- Cancers often increase sialic acid-containing glycans on their surface.
- These glycans interact with inhibitory sialic acid-binding immunoglobulin-like lectin (Siglec) receptors on immune cells, enabling immune evasion.
- The genetic basis for this cancer glycan remodeling is not well understood.
Purpose of the Study:
- To identify genetic pathways regulating the expression of Siglec-binding glycans in cancer.
- To understand the mechanisms of cancer immune evasion related to glycosylation.
Main Methods:
- Utilized gain-of-function CRISPR activation (CRISPRa) screens.
- Analyzed genetic competition between genes involved in sialylation and GlcNAcylation.
- Investigated the role of specific genes like CD24 and GAL3ST4.
Main Results:
- Siglec ligand expression is controlled by a genetic balance between α2-3 sialylation and GlcNAcylation pathways.
- Overexpression of specific "professional ligands" further aids cancer cells in binding Siglecs.
- CD24 gene expression is not essential for Siglec-10 binding.
- Identified GAL3ST4 as a potential driver of immune evasion in glioma.
Conclusions:
- Provides a genomic map of cancer-associated glycosylation.
- Highlights genetic competition as a key mechanism in cancer glycan regulation.
- Identifies novel, actionable therapeutic targets for cancer immunotherapy, including GAL3ST4 in glioma.
Related Concept Videos
CRISPR
CRISPR/Cas9 Genome Editing
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Genomics
Bone Remodeling

